摘要
目的 观察参麦注射液配合化疗治疗恶性肿瘤的临床疗效。方法 75例恶性肿瘤患者随机分为 2组 ,治疗组 4 0例予参麦注射液配合化疗治疗 ,对照组 35例单纯化疗治疗。观察 2组病例生活质量、临床证候、毒副反应及免疫功能等变化情况。结果 治疗组与对照组临床总缓解率分别为 4 7.5 %、37.1% ;生活质量变化 :治疗组与对照组改善率分别为 72 .5 %、5 4 .3% ;临床证候变化 :治疗组与对照组改善率分别为80 .0 %、6 2 .9% ;毒副反应 :治疗组白细胞下降检出率 17.5 % ,对照组白细胞下降检出率 4 2 .9%。 2组临床总缓解率及生活质量总稳定率、临床证候改善率和白细胞下降检出率比较均有极显著性差异 (P <0 .0 1)。免疫功能 :2组治疗前T淋巴细胞亚群及自然杀伤细胞 (NK细胞 )比较均无显著性差异 (P >0 .0 5 ) ;治疗后CD3、CD4 及CD4 CD8值及NK细胞活性治疗组均高于对照组 (P <0 .0 5 )。结论 参麦注射液能提高恶性肿瘤患者的生活质量、免疫功能 ,明显减轻毒副反应 ,改善临床症状 ,从而提高化疗效果 。
Objective To observe the effect of malignant tumor treated by integration of Shenmai injection and chemotherapy. Methods 75 patients with malignant tumor were randomly divided into a treatment group and a control group. In treatment group patients (n=40) were treated by integration of Shenmai injection and chemotherapy. In control group (n=35) patients were treated by only chemotherapy. Quality of life, toxic and side effect and immune function were measured in both groups. Results The total remission rate in treatment group and control group were 47.5% and 37.1%, separately. Improvement of Quality of life in treatment group and control group were 72.5% and 54.3%, separately. Detectable rate of leukocyte life in treatment group and control group17.5% and 42.9%, separately. CD 3, CD 4, CD 4/CD 8 and activity of NK cell in treatment group were higher than that in control group (P<0.05). Conclusion Shenmai injection could improve quality of life and immune function of patients with malignant tumor, and decrease toxic and side effect of chemotherapy.
出处
《河北中医》
2003年第4期256-258,共3页
Hebei Journal of Traditional Chinese Medicine
关键词
肿瘤
参麦注射液
化疗
免疫功能
Malignant tumor
Shenmai injection
Chemotherapy
Immune function
